Bristol-Myers Squibb Company
BMY
NYSE·Healthcare·Drug Manufacturers - General·Mkt cap $136.5B
$66.82
▼ -1.87%
P/E
14.72
Mkt Cap
$136.5B
52-Wk Range
$42.52–$68.64
52-Week Range
$42.52 - $68.64
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 43.0% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Extensive R&D capabilities
- Diverse therapeutic portfolio
- Strong patent protection
- Global commercial infrastructure
Bear Case
1 risk
- Low volatility (beta 0.2).
Growth
Stable outlook
Expanding oncology treatment pipeline
Value
Attractively priced below Large Cap Pharma peer average
Momentum
Hot
+20.2% over 3m
Quality
Excellent
Excellent business quality
Dividend
Solid
3.76% yield
Smart-money signal
Who's buying BMY right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
JUL 30, 2026
Reported EPS of $2.04 vs $1.60 consensus (+27.5% surprise). Revenue of $13.0B vs $11.7B expected (+10.5%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+27.5%
Revenue trend · last 8Q
—
+8%
-6%
+1%
+3%
+1%
+3%
+6%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$11.9B
$12.3B
$11.2B
$12.3B
$12.2B
$12.5B
$11.5B
$13.0B
Margins · last 8Q
Gross
71.3%
Operating
31.5%
Profit
25.6%
Wall Street consensus
13 analysts · 54% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
54%
Hold
46%
Sell
0%
Median Price Target
—
Latest: Bernstein · Aug 5, 2026
vs Industry
How BMY stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related